Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
Sign Up to like & getrecommendations! Published in 2020 at "European journal of pharmacology"
DOI: 10.1016/j.ejphar.2020.173114
Abstract: The clinical benefit of lipid-lowering therapies is to reduce circulating levels of atherogenic particles and to ameliorate the risk of atherosclerotic cardiovascular disease (ASCVD). The completion of two major clinical trials on PCSK9 inhibitors (PCSK9i),… read more here.
Keywords: pcsk9 inhibitors; clinical trials; lipid lowering; therapy ... See more keywords